All In Biotech

Drug Trial Radar · NCT05836948

The Clinical Study of SHR-9839 for Injection in Patients With Advanced Solid Tumors

An Open-label, Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-9839 for Injection in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Aug 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

174

Planned (sponsor's estimate)

Start

May 18, 2023

Primary completion

May 1, 2026

Study completion Jun 1, 2026

Sponsor

Sponsor type
Industry
First posted
May 1, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is an open-label, phase I clinical trial of SHR-9839 in patients with advanced solid tumors. The whole study is divided into three stages: dose escalation, dose expansion and efficacy expansion.

Conditions

  • Advanced Solid Tumor

Interventions

  • SHR-9839Drug

    Weekly fixed dose injection of SHR-9839

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum tolerated dose (MTD) or maximum administered dose (MAD)Time frame: On the first day of each week,4 weeks is a treatment cycle
  2. Recommended Phase 2 dose (RP2D)Time frame: From Day 1 to 90 days after last dose
  3. Incidence and severity of adverse events (AEs)/serious adverse events (SAEs) ([CTCAE] v5.0)Time frame: From Day 1 to 90 days after last dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Zhejiang Tumor Hospital

    Hangzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.